CoChat

Anandamide Suppresses Proliferation and Cytokine Release from Primary Human T-Lymphocytes Mainly via CB2 Receptors

Open access

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Anandamide (AEA) is an endogenous lipid mediator that exerts several effects in the brain as well as in peripheral tissues. These effects are mediated mainly by two types of cannabinoid receptors, named CB(1)R and CB(2)R, making AEA a prominent member of the "endocannabinoid" family. Also immune cells express CB(1) and CB(2) receptors, and possess the whole machinery responsible for endocannabinoid metabolism. Not surprisingly, evidence has been accumulated showing manifold roles of endocannabinoids in the modulation of the immune system. However, details of such a modulation have not yet been disclosed in primary human T-cells. METHODOLOGY/SIGNIFICANCE: In this investigation we used flow cytometry and ELISA tests, in order to show that AEA suppresses proliferation and release of cytokines like IL-2, TNF-alpha and INF-gamma from activated human peripheral T-lymphocytes. However, AEA did not exert any cytotoxic effect on T-cells. The immunosuppression induced by AEA was mainly dependent on CB(2)R, since it could be mimicked by the CB(2)R selective agonist JWH-015, and could be blocked by the specific CB(2)R antagonist SR144528. Instead the selective CB(1)R agonist ACEA, or the selective CB(1)R antagonist SR141716, were ineffective. Furthermore, we demonstrated an unprecedented immunosuppressive effect of AEA on IL-17 production, a typical cytokine that is released from the unique CD4+ T-cell subset T-helper 17. CONCLUSIONS/SIGNIFICANCE: Overall, our study investigates for the first time the effects of the endocannabinoid AEA on primary human T-lymphocytes, demonstrating that it is a powerful modulator of immune cell functions. In particular, not only we clarify that CB(2)R mediates the immunosuppressive activity of AEA, but we are the first to describe such an immunosuppressive effect on the newly identified Th-17 cells. These findings might be of crucial importance for the rational design of new endocannabinoid-based immunotherapeutic approaches.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0008688

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Analysis of CB1R and CB2R expression in resting and activated primary human T-lymphocytes. Freshly isolated T-lymphocytes were either left untreated or treated with 5 µg/ml anti-CD3 and 2 µg/ml anti-CD28 for the indicated periods of time (24–72 hours). Panels A–D: Cells were lysed and the homogenates were assayed for CB1R and CB2R protein by Western blot analysis. CB1R and CB2R protein levels were quantified by densitometric analysis, and were normalized to beta-actin. The results were expressed as total amount of receptors over 24 hours and 72 hours of stimulation (A, B and C) (average value of all samples) as well as CB2R to CB1R ratio (Panel D). Panel E: Cells were washed in PBS, and then mRNA was isolated and analysed by qRT-PCR using specific primers for CB1R and CB2R. Data are representative of 4 independent experiments.
Figure 1 Analysis of CB1R and CB2R expression in resting and activated primary human T-lymphocytes. Freshly isolated T-lymphocytes were either left untreated or treated with 5 µg/ml anti-CD3 and 2 µg/ml anti-CD28 for the indicated periods of time (24–72 hours). Panels A–D: Cells were lysed and the homogenates were assayed for CB1R and CB2R protein by Western blot analysis. CB1R and CB2R protein levels were quantified by densitometric analysis, and were normalized to beta-actin. The results were expressed as total amount of receptors over 24 hours and 72 hours of stimulation (A, B and C) (average value of all samples) as well as CB2R to CB1R ratio (Panel D). Panel E: Cells were washed in PBS, and then mRNA was isolated and analysed by qRT-PCR using specific primers for CB1R and CB2R. Data are representative of 4 independent experiments.CC BY · PubMed Central
Figure 2 Surface expression of CB1R and CB2R on primary human T-lymphocytes. Freshly isolated human T-lymphocytes were stimulated or not with anti-CD3 and anti-CD28 for 24 hours. Panels A–B: Surface expression of CB1R and CB2R was reported as MIF (medium intensity of fluorescence) values on a FACS-Canto, gating for CD4+CD3+ and CD4−CD3+ cells (A), and by confocal microscopy staining with anti-CD3, and anti-CB1R or anti-CB2R (B). Panel C: Resting or activated T-cells were either left untreated or incubated with 2.5 µM CP55.940 (CP), 20 µg/ml saponin, 25 µM GDP and 0.3 nM [35S]GTPγS. The amount of [35S]GTPγS bound is reported as counts per min (cpm) per 2.5×106 cells. * Indicates p<0.005 versus CD3/CD28-treated cells. Data are representative of 4 independent experiments.
Figure 2 Surface expression of CB1R and CB2R on primary human T-lymphocytes. Freshly isolated human T-lymphocytes were stimulated or not with anti-CD3 and anti-CD28 for 24 hours. Panels A–B: Surface expression of CB1R and CB2R was reported as MIF (medium intensity of fluorescence) values on a FACS-Canto, gating for CD4+CD3+ and CD4−CD3+ cells (A), and by confocal microscopy staining with anti-CD3, and anti-CB1R or anti-CB2R (B). Panel C: Resting or activated T-cells were either left untreated or incubated with 2.5 µM CP55.940 (CP), 20 µg/ml saponin, 25 µM GDP and 0.3 nM [35S]GTPγS. The amount of [35S]GTPγS bound is reported as counts per min (cpm) per 2.5×106 cells. * Indicates p<0.005 versus CD3/CD28-treated cells. Data are representative of 4 independent experiments.CC BY · PubMed Central
Figure 3 Effect of AEA on cell proliferation versus cell viability in anti-CD3/anti-CD28-stimulated T-lymphocytes. Purified resting or CD3/CD28-activated T-lymphocytes (1×105 cells/well) were either left untreated or treated with 2.5 µM AEA and/or cannabinoid receptors agonists or antagonists (each at 1.0 µM). Cells were labelled by means of CFDA-staining as well as by 7-AAD dye, and proliferating cells were analyzed with Flow Cytometry as described in Materials and Methods.
Figure 3 Effect of AEA on cell proliferation versus cell viability in anti-CD3/anti-CD28-stimulated T-lymphocytes. Purified resting or CD3/CD28-activated T-lymphocytes (1×105 cells/well) were either left untreated or treated with 2.5 µM AEA and/or cannabinoid receptors agonists or antagonists (each at 1.0 µM). Cells were labelled by means of CFDA-staining as well as by 7-AAD dye, and proliferating cells were analyzed with Flow Cytometry as described in Materials and Methods.CC BY · PubMed Central
Figure 4 Effect of AEA on IL-2 dependent anti-CD3/anti-CD28-stimulated T-cell proliferation. Purified resting or CD3/CD28-activated T-lymphocytes (1×105 cells/well) were either left untreated or treated with 2.5 µM AEA and/or cannabinoid receptors agonists or antagonists (each at 1.0 µM). Panel A: Treated or untreated cells were incubated overnight with [3H]-thymidine. Levels of [3H]-thymidine incorporation were measured as reported in Materials and Methods. Data were reported as the mean ± SD of 8 independent experiments. * Indicates p<0.001 versus CTRL cells, # p<0.01 versus CD3/CD28-treated cells, § p<0.001 versus CD3/CD28+AEA-treated cells, and Δ p<0.01 versus CD3/CD28+JWH-015-treated cells. Panel B: Supernatants of treated or untreated cells cultured for 24 hours were collected, and IL-2 levels were quantified by means of ELISA. Data are reported as the mean (± SD) of 6 independent experiments. * Indicates p<0.001 versus CTRL cells, # p<0.01 versus CD3/CD28-treated cells, § p<0.05 versus CD3/CD28+AEA-treated cells, §§ p<0.001 versus CD3/CD28+AEA-treated cells, and Δ p<0.01 versus CD3/CD28+JWH-015-treated cells.
Figure 4 Effect of AEA on IL-2 dependent anti-CD3/anti-CD28-stimulated T-cell proliferation. Purified resting or CD3/CD28-activated T-lymphocytes (1×105 cells/well) were either left untreated or treated with 2.5 µM AEA and/or cannabinoid receptors agonists or antagonists (each at 1.0 µM). Panel A: Treated or untreated cells were incubated overnight with [3H]-thymidine. Levels of [3H]-thymidine incorporation were measured as reported in Materials and Methods. Data were reported as the mean ± SD of 8 independent experiments. * Indicates p<0.001 versus CTRL cells, # p<0.01 versus CD3/CD28-treated cells, § p<0.001 versus CD3/CD28+AEA-treated cells, and Δ p<0.01 versus CD3/CD28+JWH-015-treated cells. Panel B: Supernatants of treated or untreated cells cultured for 24 hours were collected, and IL-2 levels were quantified by means of ELISA. Data are reported as the mean (± SD) of 6 independent experiments. * Indicates p<0.001 versus CTRL cells, # p<0.01 versus CD3/CD28-treated cells, § p<0.05 versus CD3/CD28+AEA-treated cells, §§ p<0.001 versus CD3/CD28+AEA-treated cells, and Δ p<0.01 versus CD3/CD28+JWH-015-treated cells.CC BY · PubMed Central
Figure 5 Effect of AEA on TNF-α versus IFN-γ production in activated T-lymphocytes. T-lymphocytes (1×105 cells/well) were either left untreated or treated with 2.5 µM AEA and/or cannabinoid receptors agonists or antagonists (each at 1.0 µM). Cells were then stimulated with PMA/ionomycin for 6 hours and stained intracellularly with anti-TNFα-APC and anti-IFNγ-PE. Levels of intracellular cytokine production were analyzed by flow cytometry, as detailed in Materials and Methods, and represent 8 independent experiments.
Figure 5 Effect of AEA on TNF-α versus IFN-γ production in activated T-lymphocytes. T-lymphocytes (1×105 cells/well) were either left untreated or treated with 2.5 µM AEA and/or cannabinoid receptors agonists or antagonists (each at 1.0 µM). Cells were then stimulated with PMA/ionomycin for 6 hours and stained intracellularly with anti-TNFα-APC and anti-IFNγ-PE. Levels of intracellular cytokine production were analyzed by flow cytometry, as detailed in Materials and Methods, and represent 8 independent experiments.CC BY · PubMed Central
Figure 6 Effect of AEA on IL-17 versus IFN-γ production in activated T-lymphocytes. T-lymphocytes (1×105 cells/well) were either left untreated or treated with 2.5 µM AEA and/or cannabinoid receptors agonists or antagonists (each at 1.0 µM). Cells were then stimulated with PMA/ionomycin for 6 hours and stained intracellularly with anti-IL17-PE and anti-IFNγ-APC. Levels of intracellular cytokine production were analyzed by flow cytometry, as detailed in Materials and Methods, and represent 8 independent experiments.
Figure 6 Effect of AEA on IL-17 versus IFN-γ production in activated T-lymphocytes. T-lymphocytes (1×105 cells/well) were either left untreated or treated with 2.5 µM AEA and/or cannabinoid receptors agonists or antagonists (each at 1.0 µM). Cells were then stimulated with PMA/ionomycin for 6 hours and stained intracellularly with anti-IL17-PE and anti-IFNγ-APC. Levels of intracellular cytokine production were analyzed by flow cytometry, as detailed in Materials and Methods, and represent 8 independent experiments.CC BY · PubMed Central
Figure 7 Effect of AEA on cytokine release in anti-CD3/anti-CD28-stimulated T-lymphocytes. Purified resting or CD3/CD28-activated T-lymphocytes (1×105 cells/well) were either left untreated or treated with 2.5 µM AEA and/or cannabinoid receptors agonists or antagonists (each at 1.0 µM). Supernatants of treated or untreated cells cultured for 24 hours were collected, and TNF-α (Panel A) and IFN-γ (Panel B) levels were quantified by means of ELISA. Data were reported as the mean (± SD) of 6 independent experiments. In panel (A), * indicates p<0.01 versus CTRL cells, # p<0.01 versus CD3/CD28-treated cells, § p<0.01 versus CD3/CD28+AEA-treated cells, and Δ p<0.01 versus CD3/CD28+JWH-015-treated cells. In panel (B), *indicates p<0.01 versus CTRL cells, # p<0.01 versus CD3/CD28-treated cells, § p<0.05 versus CD3/CD28+AEA-treated cells, and Δ p<0.05 versus CD3/CD28+JWH-015-treated cells.
Figure 7 Effect of AEA on cytokine release in anti-CD3/anti-CD28-stimulated T-lymphocytes. Purified resting or CD3/CD28-activated T-lymphocytes (1×105 cells/well) were either left untreated or treated with 2.5 µM AEA and/or cannabinoid receptors agonists or antagonists (each at 1.0 µM). Supernatants of treated or untreated cells cultured for 24 hours were collected, and TNF-α (Panel A) and IFN-γ (Panel B) levels were quantified by means of ELISA. Data were reported as the mean (± SD) of 6 independent experiments. In panel (A), * indicates p<0.01 versus CTRL cells, # p<0.01 versus CD3/CD28-treated cells, § p<0.01 versus CD3/CD28+AEA-treated cells, and Δ p<0.01 versus CD3/CD28+JWH-015-treated cells. In panel (B), *indicates p<0.01 versus CTRL cells, # p<0.01 versus CD3/CD28-treated cells, § p<0.05 versus CD3/CD28+AEA-treated cells, and Δ p<0.05 versus CD3/CD28+JWH-015-treated cells.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

See all 236

Metadata

Authors
Cencioni, M. T., Chiurchiù, V., Catanzaro, G., Borsellino, G., Bernardi, G., Battistini, L., & Maccarrone, M.
Affiliations
  • Fondazione Santa Lucia (IT)
  • University of Teramo (IT)
  • University of Rome Tor Vergata (IT)
Corresponding author
  • Battistini, Luca
  • Maccarrone, Mauro
Venue
PLoS ONE
Published
2010-01-14
Volume
5
Issue
1
Pages
e8688
ISSN
1932-6203 (ISSN-L)
OpenAlex
W1991262879
Cited by
235
References
29
Citations by year
2026: 8 · 2025: 9 · 2024: 19 · 2023: 9 · 2022: 15 · 2021: 11 · 2020: 14 · 2019: 13 · 2018: 7 · 2017: 10 · 2016: 18 · 2015: 20 · 2014: 20 · 2013: 22 · 2012: 21
FWCI
14.33
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Archivio Istituzionale della Ricerca - Università degli Studi dell Aquila (submittedVersion)
Funders
Ministero della Salute
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
  • Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
Keywords
anandamide, endocannabinoids, CB2 receptor, CB1 receptor, T cells, immunosuppression, T cell proliferation, cytokine production, IL-17, Th17 cells, JWH-015, SR144528, SR141716, ACEA
MeSH terms
Rimonabant, Arachidonic Acids, Base Sequence, Camphanes, Enzyme-Linked Immunosorbent Assay, Flow Cytometry, Humans, Piperidines, Pyrazoles, T-Lymphocytes, Cytokines, DNA Primers, Microscopy, Confocal, Reverse Transcriptase Polymerase Chain Reaction, Receptor, Cannabinoid, CB2, Cell Proliferation, Polyunsaturated Alkamides, Endocannabinoids

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anandamide Suppresses Proliferation and Cytokine Release from Primary Human T-Lymphocytes Mainly via CB2 Receptors. https://app.cochat.ai/papers/10.1371/journal.pone.0008688
The paper
Cencioni, M. T., Chiurchiù, V., Catanzaro, G., Borsellino, G., Bernardi, G., Battistini, L., & Maccarrone, M. (2010). Anandamide Suppresses Proliferation and Cytokine Release from Primary Human T-Lymphocytes Mainly via CB2 Receptors. PLoS ONE. https://doi.org/10.1371/journal.pone.0008688

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.